Cargando…
Experience of bipolar androgen therapy (BAT) in Argentinian oncology centres
BACKGROUND: Previous studies with bipolar androgen therapy (BAT) have shown clinical activity in metastatic Castration Resistant Prostate Cancer (mCRPC) as well as the potential to re-sensitise prostate cancer cells to prior androgen receptor-targeted agents. None of these studies had tested BAT aft...
Autores principales: | Zarbá, Martín, Angel, Martin, Losco, Federico, Zarbá, Juan José, Pupilli, Juan Carlos, Chacon, Matías Rodrigo, Sade, Juan Pablo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934967/ https://www.ncbi.nlm.nih.gov/pubmed/36819799 http://dx.doi.org/10.3332/ecancer.2022.1480 |
Ejemplares similares
-
PARP inhibitors as a radiosensitizer: a future promising approach in prostate cancer?
por: Angel, Martin, et al.
Publicado: (2021) -
Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
por: Scheinberg, Morton, et al.
Publicado: (2018) -
Bipolar androgen therapy (BAT): A patient's guide
por: Denmeade, Samuel, et al.
Publicado: (2022) -
Burnout syndrome in medical oncologists during the COVID-19 pandemic: Argentinian national survey
por: Guercovich, Andres, et al.
Publicado: (2021) -
The Argentinian landscape of mycological diagnostic capacity and treatment accessibility
por: Riera, Fernando, et al.
Publicado: (2023)